On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients

Table 1 Patients’ characteristics

	n = 95 patients
Female:male	58:37 patients
Age (yr)	43 years (range 20–74 yr)
UC:CD	42:53 patients
Duration of IBD at start 6-TG	10.4 yr (SD 9.4 yr)
AZA intolerance	78 patients (82%)
6-MP intolerance	4 patients (4%)
AZA and 6-MP intolerance	13 patients (14%)
AZA or 6-MP rechallenge	36 patients (38%)
Adverse events on AZA or 6MP:	30% gastrointestinal complaints
	20% general malaise
	14% allergic reactions
	10% pancreaticotoxicity
	6% hepatotoxicity
	5% myelotoxicity
	14% rest (e.g., myalgia or alopecia)
6-TG dosage at the start	24.6 mg (range 20-40 mg)